Near-universal coverage did not usher in an era of improved utilization.

Safety, efficacy not established; some evidence points to lower long-term survival.

Higher complications were reported after complete macroscopic resection.

Benefits observed with respect to menstruation and ovulation, failure prevention.

Better detection of smaller, node-negative invasive cancers.

Differences in tumor microenvironment can lead to differential responses.

Phase 2 data show effect is driven by subset without a known BRCA mutation.

The novel Radiomic Prognostic Vector has been developed by researchers at Imperial College London and the University of Melbourne.

Research presented at Cancer Research UK’s Early Diagnosis Conference.

A positive screen warrants genetic counseling and potential genetic testing.

The guidelines relate to the medical and radiotherapeutic management of cancer pain.

"Unfounded rumours about HPV vaccines” continue to unnecessarily delay the scaling up of vaccination says International Agency for Research on Cancer.

Responses were irrespective of PD-L1 and BRCA status.

Findings affirm public health benefits.